基于计算机断层扫描的影像组学特征预测头颈部鳞状细胞癌程序性死亡配体1表达
本研究纳入157例确诊头颈部鳞状细胞癌患者,基于增强CT提取影像组学特征构建预测程序性死亡配体1表达的影像组学特征,训练集104例(阳性62例、阴性42例),外部验证集53例(阳性34例、阴性19例)。训练集和验证集区分程序性死亡配体1阳性与阴性的受试者工作特征曲线下面积分别为0.852和0.802。
要点
- 基于增强CT的影像组学特征可用于预测头颈部鳞状细胞癌程序性死亡配体1表达状态。
- 训练集受试者工作特征曲线下面积0.852,外部验证集0.802。
- 最终选取9个影像组学特征构建影像组学特征。
核心结论
- 基于增强CT的影像组学特征能够预测头颈部鳞状细胞癌程序性死亡配体1表达,训练集与验证集受试者工作特征曲线下面积分别为0.852和0.802,该模型可能有助于识别可从抗程序性死亡配体1免疫治疗中获益的头颈部鳞状细胞癌患者。
研究设计与样本
- 本研究为影像组学研究,纳入157例经确诊的头颈部鳞状细胞癌患者,均接受增强CT扫描及肿瘤程序性死亡配体1表达免疫组织化学检查;患者分为训练集104例(程序性死亡配体1阳性62例、阴性42例)和外部验证集53例(阳性34例、阴性19例);从增强CT图像提取影像组学特征构建影像组学特征并计算影像组学评分,采用受试者工作特征曲线分析评估性能。
诊断标准与关键数值
- 最终选取9个特征构建影像组学特征;该影像组学特征区分程序性死亡配体1阳性与阴性的受试者工作特征曲线下面积在训练集为0.852、在验证集为0.802。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Accurate prediction of the expression of programmed death ligand 1 (PD-L1) in head and neck squamous cell carcinoma (HNSCC) before immunotherapy is crucial. This study was performed to construct and validate a contrast-enhanced computed tomography (CECT)-based radiomics signature to predict the expression of PD-L1 in HNSCC.
METHODS: In total, 157 patients with confirmed HNSCC who underwent CECT scans and immunohistochemical examination of tumor PD-L1 expression were enrolled in this study. The patients were divided into a training set (n = 104; 62 PD-L1-positive and 42 PD-L1-negative) and an external validation set (n = 53; 34 PD-L1-positive and 19 PD-L1-negative). A radiomics signature was constructed from radiomics features extracted from the CECT images, and a radiomics score was calculated. Performance of the radiomics signature was assessed using receiver operating characteristics analysis.
RESULTS: Nine features were finally selected to construct the radiomics signature. The performance of the radiomics signature to distinguish between a PD-L1-positive and PD-L1-negative status in both the training and validation sets was good, with an area under the receiver operating characteristics curve of 0.852 and 0.802 for the training and validation sets, respectively.
CONCLUSIONS: A CECT-based radiomics signature was constructed to predict the expression of PD-L1 in HNSCC. This model showed favorable predictive efficacy and might be useful for identifying patients with HNSCC who can benefit from anti-PD-L1 immunotherapy.
KEY POINTS: • Accurate prediction of the expression of PD-L1 in HNSCC before immunotherapy is crucial. • A CECT-based radiomics signature showed favorable predictive efficacy in estimation of the PD-L1 expression status in patients with HNSCC.
引用
- Zheng, Yuan, Zhou, et al. A computed tomography-based radiomics signature for predicting expression of programmed death ligand 1 in head and neck squamous cell carcinoma. Eur Radiol. 2022. PMID: 35298679. doi:10.1007/s00330-022-08651-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。